Strong efficacy and a clean safety profile – with no cardiovascular signal – in another Phase III study bode well for filings of Zogenix's ZX008 in the fourth quarter.
Zogenix Inc.'s latest Phase III data for ZX008 (low dose fenfluramine) in the rare childhood epilepsy Dravet syndrome suggest the drug has a stronger profile compared with GW Pharmaceuticals PLC's recently approved cannabinoid drug Epidiolex.
There are some 8,000 Dravet syndrome patients in the US and up until recently no treatments were approved for the...
Optimizing Drug Pipelines With Biophysical Methods”, your view into how using biophysical techniques can enhance and streamline processes throughout the drug discovery and validation cycle.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
GSK will assume full control of mRNA shots in infectious disease, allowing CureVac to cut costs and pivot its research to oncology.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
